Joy Wolfram

Associate Professor Joy Wolfram leads an extracellular vesicle research program (24,600+ citations) with the goal of developing innovative approaches that bring the next generation of medicines directly to the clinic to alter the trajectory of life-threatening diseases, improve patient outcomes, and prolong healthy lifespans. Wolfram has joint appointments in the School of Chemical Engineering and the Australian Institute for Bioengineering and Nanotechnology at The University of Queensland, Australia (ranked 43rd globally by U.S. News & World Report). She also serves as the Research Director of the Herston Biofabrication Institute, a partnership with Metro North Health, the largest and most diverse hospital and health service in Queensland. MISSION 1) Develop a new paradigm of therapeutics (using nanotechnology and cell products) to treat life-threatening diseases that are major causes of death globally, including cardiovascular disease, kidney disease, and breast cancer 2) Save lives by manufacturing at scale, by delivering national manufacturing innovation and a skilled workforce 3) Work with a multidisciplinary team and industry partners to position Australia as a global leader in extracellular vesicle medicine Extracellular vesicles are small biomolecular packages that are crucial for intercellular communication (locally and systemically). Extracellular vesicles have promising potential to be leveraged and engineered to provide a new paradigm of therapeutics that outperform conventional pharmaceuticals due to versatile bioactive cargo. The Wolfram Laboratory is leveraging innovations in manufacturing, biological mechanisms, and drug loading of extracellular vesicles to develop therapeutics. FOCUS AREAS 1) Developing improved methods for extracellular vesicle isolation from human biofluids 2) Designing hybrid drug delivery systems with extracellular vesicle and synthetic components for a ‘best-of-both-worlds’ approach to treat cardiovascular disease and aging kidney disease 3) Understanding the role of extracellular vesicles in cancer immunoevasion and metastasis The research program has resulted in more than 100 publications in journals, such as, Nature Nanotechnology, Materials Today, and Nature Reviews Materials. The Wolfram Laboratory has collaborated with 160 universities and industry partners across 45 countries (Scopus). The research program has also been featured in more than 100 invited and keynote talks. Wolfram is actively involved in community outreach and education, including in her previous roles as the Chair of an education and outreach working group of the National Institutes of Health in the United States and the Associate Program Director of the PhD Program in Regenerative Sciences at Mayo Clinic (ranked 1st globally by Newsweek). As a TED speaker, she strives to bring science to a wide audience. She has received 49 awards from nine countries, including the 2016 Amgen Scholars Ten to Watch List (best and brightest up-and-comers in science and medicine across 42 countries), the 2019 Forbes 30 under 30 list in Health Care in the United States/Canada, the 2019 shortlist for the Nature Research Award for Inspiring Science (one of ten worldwide), and the 2021 Finnish Expatriate of the Year (past recipients include Nobel Memorial Prize winners, Millennium Technology Prize winners, and Formula 1 drivers). In the past five years, she is ranked in the top 1 percent of researchers in fields such as, extracellular vesicles, cancer, drug delivery, biology/biochemistry, and pharmacology/toxicology (Essential Science Indicators SciVal and Scholar GPS). Biomanufacturing, Bioseparation, Biotherapeutics, Breast cancer, Exosomes, Extracellular vesicles, Nanomedicine, Nanoparticles, Regenerative medicine, Scientific outreach

[2026] Platelet-derived purified exosome product (PEP): a clinical-grade lyophilized extracellular vesicle product with broad therapeutic potential, including kidney repair. Nano Research, 19 (6) 94908496. doi: 10.26599/nr.2026.94908496 [2026] Examining combined therapeutic effects of senolytics and extracellular vesicles in murine diabetic kidney disease. 32nd ISCT Scientific Annual Meeting, Dublin, Ireland, 6-9 May 2026. doi: 10.1016/j.jcyt.2026.102344 [2026] Integrative approaches to treating cellular senescence in kidney disease. Advanced Science, 13 (21) e19392, 1-24. doi: 10.1002/advs.202519392 [2026] Targeting cellular senescence in diabetic kidney disease: potential of regenerative, cell-based therapies and other senotherapeutic approaches. Kidney International, 109 (4), 684-703. d